A German cohort showed that two thirds of female pwMS stopping natalizumab because of pregnancy have a relapse, and 10% keeps disability one year after delivery. Numbers that make PML risk look good. Time to change the expert advice? multiple-sclerosis-research.org/2022/02/natali… the_MSBlog

We cannot prescribe anti-CD20 indefinitely, and there’s considerable evidence to start using it as an induction therapy. Understandably, many pwMS are not prepared to let go of the 6-monthly infusions. Would you be prepared to stop? the_MSBlog multiple-sclerosis-research.org/2022/02/ms-fut…

Serum NfL Z-scores instead of raw cut-offs are much better at predicting inflammatory disease activity in pwMS. An online tool allows to use Z-scores for DMT decisions in daily practice. Can we now flip and zip the DMT pyramid? multiple-sclerosis-research.org/2022/03/zippin…

A huge thanks to all the people with MS who helped us to design this leaflet for people with MS considering pregnancy buff.ly/3tB3xKb. You had told us you wanted a reliable leaflet to be able to look at outside of clinic appointments that you could read in your own time.

Are the Dutch also ready to embrace HSCT as a first line treatment? MSweb @msvereniging MS Research @NationalMSFonds MS center ErasMS Hersenbank MS Centrum Amsterdam UMCG Transplantatie @nvneuropsy Ide Smets @JeroenJGGeurts Hanneke Hulst @Eef111 NIN

Many pwMS struggle with DMT decisions when they have new lesions on brain MRI without new symptoms. Two attempts to better explain this clinical-MRI paradox: the topographical model of MS and road traffic. Do you stop for groceries at night? the_MSBlog multiple-sclerosis-research.org/2022/05/clinic…

This is a superb post. I also struggle to understand why someone would fail to take the neurologist's advice. I guess Ide Smets has put her finger on it when she suggests it may be a form of denial (my words). MS is constantly vandalising our brains. bit.ly/3vPXS4f

Many pwMS need to gain a new expertise: overcoming administrative hurdles to gain access to crucial healthcare services such as rehab. In the UK this is the red tape, in the Netherlands a purple crocodile. Do you have any in your pool? multiple-sclerosis-research.org/page/3/@the_MS… MS center ErasMS

During clincics, we are often too much focused on drugs, and forget to mention the second most-effective MS treatment: exercise. To compensate, I discuss my insights together with theMSguide.com 🧠 in this podcast. #brainhealth open.spotify.com/episode/0bK1Ar…

The position of aHSCT in the MS treatment landscape is a source of debate, and for many pwMS it’s unclear who can benefit. In early aggressive MS it’s clear, but for progressive MS the risk/benefit profile of aHSCT shifts. the_MSBlog multiple-sclerosis-research.org/2022/06/projec…

There’s no exit strategy for pwMS on anti-CD20 atm. Some argue there’s no need to exit, some argue to extend intervals and we argue to stop anti-CD20 after 4 infusion cycli. Do you agree? journals.sagepub.com/doi/10.1177/13… MS center ErasMS

Rituximab (anti-CD20) is a more potent MS drug than dimethyl fumarate. The bigger question: is it better than the more costly ocrelizumab? Three possible answers: an official, a real and a right one. Which one do you prefer?the_MSBlog multiple-sclerosis-research.org/2022/08/haute-…

Russians: Do you want to join Holland? (Namens Nederland, een referendum voor alle Russen: willen jullie bij Nederland horen?)

In simulated MS cohorts, lesion detection algorithms argue to be disease-modifying by detection more lesions, triggering early treatment switches and preventing disability. Nice feature or necessary add-on intervention? multiple-sclerosis-research.org/2022/10/pain-q…

Very 🔥 debate with christine lebrun frenay and Barbara Willekens on a late breaking topic: should we start treating radiologically isolated syndrome? A struggle between biology and disease, that needs to be addressed by new RIS criteria. ECTRIMS

Past & current #BartsMS ECTRIMS fellows Ide Smets Drs Saul Reyes & Manuel Salavisa linking up with Centre for Preventive Neurology senior lecturer Dr Alison Thomson at #ECTRIMS2022 I amsterdam

This is a vastly improved tool to help make the best DMT choices. clinicspeak.com/dmt/ Question 2 is a real no-brainer! Kudos to Ide Smets

Not all MS drugs are created equal! In MS Center ErasMS gebruiken we daarom vanaf nu de Nederlandse versie van de #clinicspeak medicatie keuzetool. Vrij beschikbaar voor alle MS centra en pmMS. DM voor een visitekaartje! clinicspeak.com/dmt/nl

Controversy ⚖️ Pre-symptomatic #MultipleSclerosis or radiologically isolated syndrome #RIS should be actively monitored and treated. 🧵1/4 Link to commentary ▶️ journals.sagepub.com/doi/abs/10.117…

Ruth Dobson (UK) and Ide Smets (The Netherlands) explore the practicalities of therapeutic sequencing options in MS. Watch now: ow.ly/FTEX50OMQV5 #MedTwitter #Neurology #NeuroImmunology #MS #MultipleSclerosis #MedEd